A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Alastair Greystoke(Newcastle University), William P. Steward(University of Leicester), Simon Pacey(Royal Marsden NHS Foundation Trust), Anne Thomas(Leicester Royal Infirmary), Sarah P. Blagden(Churchill Hospital), R. Molife(Royal Marsden NHS Foundation Trust), A. Jenner(Daiichi Sankyo (United Kingdom)), Edwina N. Scott(University of Leicester), Gerhardt Attard(Royal Marsden NHS Foundation Trust), D Sarkar(Royal Marsden NHS Foundation Trust), Laura Vidal(Vall d'Hebron Hospital Universitari)

Annals of Oncology

May 25, 2006

Cited by 24

|Cell|2015|3.6k

|New England Journal of Medicine|2015|2.2k

|Nature reviews. Cancer|2015|1.4k

|Cell|2015|576

|Biochemical Journal|1986|486

Related Papers